Abstract:Purpose: Lung cancer is a major cause of morbidity and mortality globally, necessitating the identification of predictive markers for effective immunotherapy. Mutations in SWI/SNF chromatin remodeling complex genes were reported sensitized human tumors to immune checkpoint inhibitors (ICIs), but the underlying mechanisms are unclear. This study aims to investigate the association between SWI/SNF gene ARID1B mutation and ICI response in non-small cell lung cancer (NSCLC) patients, to explore the functional consequences of ARID1B mutation on DNA damage response, immune microenvironment, and cGAS-STING pathway activation. Methods: TCGA LUAD, LUSC, and AACR GENIE data are analyzed to assess ARID1B mutation status in NSCLC patients. Prognostic analysis evaluates the effect of ARID1B mutation on patient outcomes. In vitro experiments carried to investigate the consequences of ARID1B knockdown on DNA damage response and repair. The immune microenvironment is assessed based on ARID1B expression, and the relationship between ARID1B and the cGAS-STING pathway is explored. Results: ARID1B mutation frequency is 5.7% in TCGA databases and 4.4% in the AACR GENIE project. NSCLC patients with ARID1B mutation showed improved overall and progression-free survival following ICIs treatment. ARID1B knockdown in lung cancer cell lines enhances DNA damage, impairs DNA repair, alters chromatin accessibility, and activates the cGAS-STING pathway. ARID1B deficiency is associated with immune suppression, indicated by reduced immune scores, decreased immune cell infiltration, and negative correlations with immune-related cell types and functions. Conclusion: ARID1B mutation may predict improved response to ICIs in NSCLC patients. ARID1B mutation leads to impaired DNA damage response and repair, altered chromatin accessibility, and cGAS-STING pathway activation. These findings provide insights into ARID1B's biology and therapeutic implications in lung cancer, highlighting its potential as a target for precision medicine and immunotherapy. Further validation and clinical studies are warranted.

Supplementary Table from Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability

Chromatin remodeling induced by ARID1A loss in lung cancer promotes glycolysis and confers JQ1 vulnerability

Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Table 1 from Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis

Clinical Outcome and Molecular Landscape of Patients with ARID1A-loss Gastric Cancer.

Supplementary Table S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

ARID1A Deficiency Weakens BRG1-RAD21 Interaction That Jeopardizes Chromatin Compactness and Drives Liver Cancer Cell Metastasis.

Table S11 from Activation of PI3K/AKT Pathway is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer

Supplementary Figure S9 from the N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma

Supplementary Table S1 from Lactate Induces Tumor Progression Via LAR Motif-Dependent Yin-Yang 1 Degradation

Table S1 from Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation

Supplementary Table S2 from Lactate Induces Tumor Progression Via LAR Motif-Dependent Yin-Yang 1 Degradation

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung Cancer

Table S3 from Transcription Elongation Machinery is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells

Targeting HSPA1A in ARID2-deficient lung adenocarcinoma

Table S15 from Activation of PI3K/AKT Pathway is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer

ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis